Prognostic significance of serum prolactin levels in advanced breast cancer.

Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol. The mean level of prolactin was higher, and there were more individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowsett, M., McGarrick, G. E., Harris, A. L., Coombes, R. C., Smith, I. E., Jeffcoate, S. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011370/
https://www.ncbi.nlm.nih.gov/pubmed/6860546
Descripción
Sumario:Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol. The mean level of prolactin was higher, and there were more individuals with levels of prolactin greater than or equal to 500 mIUl-1, in the group of patients who did not respond to treatment. Of the patients whose disease progressed, those with prolactin levels greater than or equal to 500 mIUl-1 had a significantly shorter survival. It appears that high prolactin levels indicate a poor prognosis to endocrine therapy and the probability of a shorter than average survival time.

Ejemplares similares